Essentiality of FASII pathway for Staphylococcus aureus
暂无分享,去创建一个
Koen Andries | K. Andries | N. Lounis | A. Koul | J. Guillemont | R. Gilissen | Anil Koul | W. Balemans | K. Simmen | Jerome Guillemont | Nacer Lounis | Wendy Balemans | Ron Gilissen | Kenny Simmen
[1] C. Rock,et al. Mechanistic diversity and regulation of Type II fatty acid synthesis. , 2002, Biochemical Society transactions.
[2] B. Finlay,et al. Exploitation of mammalian host cell functions by bacterial pathogens. , 1997, Science.
[3] B. Staels,et al. Type II fatty acid synthesis is not a suitable antibiotic target for Gram-positive pathogens , 2009, Nature.
[4] R. Altenbern,et al. Cerulenin-Inhibited Cells of Staphylococcus aureus Resume Growth When Supplemented with Either a Saturated or an Unsaturated Fatty Acid , 1977, Antimicrobial Agents and Chemotherapy.
[5] R. Heath,et al. Fatty acid biosynthesis as a target for novel antibacterials. , 2004, Current opinion in investigational drugs.
[6] Chang Ki Kim,et al. In Vitro Activities of CG400549, a Novel FabI Inhibitor, against Recently Isolated Clinical Staphylococcal Strains in Korea , 2007, Antimicrobial Agents and Chemotherapy.
[7] Michael Otto,et al. Staphylococcus aureus Resistance to Human Defensins and Evasion of Neutrophil Killing via the Novel Virulence Factor Mprf Is Based on Modification of Membrane Lipids with l-Lysine , 2001, The Journal of experimental medicine.
[8] D. de Mendoza,et al. Isolation and Characterization of Unsaturated Fatty Acid Auxotrophs of Streptococcus pneumoniae and Streptococcus mutans , 2007, Journal of bacteriology.
[9] Jun Wang,et al. Platensimycin is a selective FabF inhibitor with potent antibiotic properties , 2006, Nature.
[10] Yinduo Ji,et al. Validation of antibacterial mechanism of action using regulated antisense RNA expression in Staphylococcus aureus. , 2004, FEMS microbiology letters.
[11] A. Ullrich,et al. Interplay between mycobacteria and host signalling pathways , 2004, Nature Reviews Microbiology.
[12] C. Rock,et al. Membrane lipid homeostasis in bacteria , 2008, Nature Reviews Microbiology.
[13] C. Vilchèze,et al. Transfer of a point mutation in Mycobacterium tuberculosis inhA resolves the target of isoniazid , 2006, Nature Medicine.
[14] R J Heath,et al. Lipid biosynthesis as a target for antibacterial agents. , 2001, Progress in lipid research.
[15] C. Weidenmaier,et al. DltABCD- and MprF-Mediated Cell Envelope Modifications of Staphylococcus aureus Confer Resistance to Platelet Microbicidal Proteins and Contribute to Virulence in a Rabbit Endocarditis Model , 2005, Infection and Immunity.
[16] Martha S. Head,et al. Discovery of a Novel and Potent Class of FabI-Directed Antibacterial Agents , 2002, Antimicrobial Agents and Chemotherapy.